Evidence map›Paper›PMID 28394406›Full record

ArticleHistopathology2017

PBRM1 loss is a late event during the development of cholangiocarcinoma.

Claudio Luchini, Scott A Robertson, Seung-Mo Hong, Matthäus Felsenstein, Robert A Anders, Antonio Pea, Alessia Nottegar, Nicola Veronese, Jin He, Matthew J Weiss and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Histopathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Current issues in molecular biology · 2024
    Article
  6. Article
  7. Cholangiocarcinoma and liver transplantation: What we know so far?World journal of gastrointestinal pathophysiology · 2021
    Review
  8. Article
  9. Article
  10. Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinoma.Virchows Archiv : an international journal of pathology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Claudio LuchiniDepartment of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.ORCID http://orcid.org/0000-0003-4901-4908
Scott A RobertsonDepartment of Pathology, Johns Hopkins University, Baltimore, MD, USA.
Seung-Mo HongDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Matthäus FelsensteinDepartment of Pathology, Johns Hopkins University, Baltimore, MD, USA.
Robert A AndersDepartment of Pathology, Johns Hopkins University, Baltimore, MD, USA.
Antonio PeaDepartment of Surgery, University and Hospital Trust of Verona, Verona, Italy.
Alessia NottegarDepartment of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.
Nicola VeroneseNational Research Council, Neuroscience Institute, Aging Branch, Padua, Italy.
Jin HeDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Matthew J WeissDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Paola CapelliDepartment of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.
Aldo ScarpaDepartment of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.
Pedram ArganiDepartment of Pathology, Johns Hopkins University, Baltimore, MD, USA.
Payal KapurDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Laura D WoodDepartment of Pathology, Johns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-3096-652X
Johns Hopkins University · USUniversity of Verona · ITNeuroscience Institute · ITThe University of Texas Southwestern Medical Center · USUlsan College · KR

Funding

Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI KERN, SCOTT E · 1993 to 2022
$54.6M
University of Texas Southwestern Medical Center SPORE in Kidney CancerP50CA196516 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI James Brugarolas · 2016 to 2026
$24.7M
Characterization of the Molecular Determinants of High-Grade Dysplasia in Pancreatic Cancer Precursor LesionsK08DK107781 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI WOOD, LAURA DELONG · 2016 to 2020
$846k
NCI NIH HHS P50 CA062924NCI NIH HHS P50 CA196516NIDDK NIH HHS K08 DK107781
6 · The paper itself

Abstract

aimsSomatic mutations in genes encoding chromatin remodellers have been reported recently in several cancer types, including approximately half of cholangiocarcinomas. One of the most commonly mutated chromatin remodellers in cholangiocarcinoma is the Polybromo-1 (PBRM1) gene located on chromosome 3p21, which encodes a subunit of the SWI/SNF complex. The aim of this study was to determine the timing of PBRM1 mutations in biliary carcinogenesis. METHODS AND

resultsIn order to accomplish this goal, we used immunohistochemistry to assess PBRM1 protein expression in a series of precursor lesions and invasive biliary carcinomas. Previous studies have correlated loss of protein expression on immunohistochemistry with inactivating mutations in this tumour suppressor gene. We found that PBRM1 loss occurred in approximately 26% of invasive cancers, but PBRM1 expression was retained in all biliary intra-epithelial neoplasia (BilIN) specimens, including 25 intrahepatic BilINs and 19 gallbladder BilINs.

conclusionsThese findings indicate that PBRM1 mutation (and resultant loss of expression) is a late event during biliary carcinogenesis. In addition, we confirm a lack of prognostic significance of PBRM1 status in invasive intrahepatic cholangiocarcinoma. This study provides important insights into the basic mechanisms of chromatin remodelling genes in carcinogenesis.

Indexed as

Bile Duct NeoplasmsCell Transformation, NeoplasticCholangiocarcinomaDNA-Binding ProteinsHumansKaplan-Meier EstimateMutationNuclear ProteinsPrognosisProportional Hazards ModelsTranscription FactorsDNA-Binding ProteinsNuclear ProteinsPBRM1 protein, humanTranscription Factorsbiliary dysplasiaBilINcholangiocarcinomachromatin remodellingPBRM1

Identifiers

PMID28394406
PMCPMC5552448
OpenAlexW2606503150

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.